Sourabh Lahoti1, Sankalp Gokhale2, Louis Caplan2, Patrik Michel2, Yves Samson2, Charlotte Rosso2, Kaustubh Limaye2, Archana Hinduja2, Aneesh Singhal2, Syed Ali2, Luther Creed Pettigrew2, Richard Kryscio2, Nikita Dedhia2, Shirish Hastak2, David S Liebeskind2. 1. From the Department of Neurology (S.L., L.C.P.) and Department of Biostatistics (R.K.), University of Kentucky, Lexington; Department of Neurology, Duke University Medical Center, Durham, NC (S.G); Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA (L.C.); Department of Neurology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland (P.M.); Department of Neurology, Pitié-Salpêtrière Hospital, APHP, University Pierre et Marie Curie, Paris, France (Y.S., C.R.); Department of Neurology, University of Arkansas, Little Rock (K.L., A.H.); Department of Neurology, Massachusetts General Hospital, Boston (A.S., S.A.); Center for Brain and Nervous System, Kokilaben Dhirubhai Ambani Hospital, Mumbai, India (N.D., S.H.); and University of California, Los Angeles (D.S.L.). dr.s.lahoti@gmail.com. 2. From the Department of Neurology (S.L., L.C.P.) and Department of Biostatistics (R.K.), University of Kentucky, Lexington; Department of Neurology, Duke University Medical Center, Durham, NC (S.G); Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA (L.C.); Department of Neurology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland (P.M.); Department of Neurology, Pitié-Salpêtrière Hospital, APHP, University Pierre et Marie Curie, Paris, France (Y.S., C.R.); Department of Neurology, University of Arkansas, Little Rock (K.L., A.H.); Department of Neurology, Massachusetts General Hospital, Boston (A.S., S.A.); Center for Brain and Nervous System, Kokilaben Dhirubhai Ambani Hospital, Mumbai, India (N.D., S.H.); and University of California, Los Angeles (D.S.L.).
Abstract
BACKGROUND AND PURPOSE: None of the randomized trials of intravenous tissue-type plasminogen activator reported vascular imaging acquired before thrombolysis. Efficacy of tissue-type plasminogen activator in stroke without arterial occlusion on vascular imaging remains unknown and speculative. METHODS: We performed a retrospective, multicenter study to collect data of patients who presented to participating centers during a 5-year period with ischemic stroke diagnosed by clinical examination and MRI and with imaging evidence of no vascular occlusion. These patients were divided into 2 groups: those who received thrombolytic therapy and those who did not. Primary outcome measure of the study was excellent clinical outcome defined as modified Rankin Scale of 0 to 1 at 90 days from stroke onset. Secondary outcome measures were good clinical outcome (modified Rankin Scale, 0-2) and perfect outcome (modified Rankin Scale, 0). Safety outcome measures were incidence of symptomatic intracerebral hemorrhage and poor outcome (modified Rankin Scale, 4-6). RESULTS: A total of 256 patients met study criteria, 103 with thrombolysis and 153 without. Logistic regression analysis showed that patients who received thrombolysis had more frequent excellent outcomes with odds ratio of 3.79 (P<0.01). Symptomatic intracerebral hemorrhage was more frequent in thrombolysis group (4.9 versus 0.7%; P=0.04). Thrombolysis led to more frequent excellent outcome in nonlacunar group with odds ratio 4.90 (P<0.01) and more frequent perfect outcome in lacunar group with odds ratio 8.25 (P<0.01). CONCLUSIONS: This study provides crucial data that patients with ischemic stroke who do not have visible arterial occlusion at presentation may benefit from thrombolysis.
BACKGROUND AND PURPOSE: None of the randomized trials of intravenous tissue-type plasminogen activator reported vascular imaging acquired before thrombolysis. Efficacy of tissue-type plasminogen activator in stroke without arterial occlusion on vascular imaging remains unknown and speculative. METHODS: We performed a retrospective, multicenter study to collect data of patients who presented to participating centers during a 5-year period with ischemic stroke diagnosed by clinical examination and MRI and with imaging evidence of no vascular occlusion. These patients were divided into 2 groups: those who received thrombolytic therapy and those who did not. Primary outcome measure of the study was excellent clinical outcome defined as modified Rankin Scale of 0 to 1 at 90 days from stroke onset. Secondary outcome measures were good clinical outcome (modified Rankin Scale, 0-2) and perfect outcome (modified Rankin Scale, 0). Safety outcome measures were incidence of symptomatic intracerebral hemorrhage and poor outcome (modified Rankin Scale, 4-6). RESULTS: A total of 256 patients met study criteria, 103 with thrombolysis and 153 without. Logistic regression analysis showed that patients who received thrombolysis had more frequent excellent outcomes with odds ratio of 3.79 (P<0.01). Symptomatic intracerebral hemorrhage was more frequent in thrombolysis group (4.9 versus 0.7%; P=0.04). Thrombolysis led to more frequent excellent outcome in nonlacunar group with odds ratio 4.90 (P<0.01) and more frequent perfect outcome in lacunar group with odds ratio 8.25 (P<0.01). CONCLUSIONS: This study provides crucial data that patients with ischemic stroke who do not have visible arterial occlusion at presentation may benefit from thrombolysis.
Authors: Wolfgang G Kunz; Wieland H Sommer; Lukas Havla; Franziska Dorn; Felix G Meinel; Olaf Dietrich; Grete Buchholz; Birgit Ertl-Wagner; Kolja M Thierfelder Journal: Eur Radiol Date: 2016-10-08 Impact factor: 5.315
Authors: Grant Mair; Rüdiger von Kummer; Alessandro Adami; Philip M White; Matthew E Adams; Bernard Yan; Andrew M Demchuk; Andrew J Farrall; Robin J Sellar; Eleni Sakka; Jeb Palmer; David Perry; Richard I Lindley; Peter A G Sandercock; Joanna M Wardlaw Journal: Stroke Date: 2016-12-22 Impact factor: 7.914
Authors: Huiqiao Tian; Mark W Parsons; Christopher R Levi; Xin Cheng; Richard I Aviv; Neil J Spratt; Timothy J Kleinig; Billy O'Brien; Kenneth S Butcher; Longting Lin; Jingfen Zhang; Qiang Dong; Chushuang Chen; Andrew Bivard Journal: Front Neurol Date: 2018-06-06 Impact factor: 4.003
Authors: Grant Mair; Rüdiger von Kummer; Zoe Morris; Anders von Heijne; Nick Bradey; Lesley Cala; André Peeters; Andrew J Farrall; Alessandro Adami; Gillian Potter; Geoff Cohen; Peter A G Sandercock; Richard I Lindley; Joanna M Wardlaw Journal: Neurology Date: 2015-12-09 Impact factor: 9.910